Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer

G. Megaro; E. Miele; G. P. Spinelli; I. Alessi; Baldo G. Del; R. Cozza; I. Russo; Pasquale M. D. De; M. G. Cefalo; P. Toma; A. Carai; Ruscio V. Di; Ioris M. A. De; Angela Mastronuzzi

doi:10.1002/cnr2.1483

Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer

G. Megaro^*
, E. Miele
, G. P. Spinelli
, I. Alessi
, Baldo G. Del
, R. Cozza
, I. Russo
, Pasquale M. D. De
, M. G. Cefalo
, P. Toma
, A. Carai
, Ruscio V. Di
, Ioris M. A. De
, Angela Mastronuzzi

^*Corresponding author

IRCCS Ospedale pediatrico Bambino Gesù - Roma

Research output: Contribution to journal › Article

Abstract

Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Cancer Reports
Volume	5
Issue number	3
DOIs	https://doi.org/10.1002/cnr2.1483
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Keywords

adenocarcinoma
adolescence
ALK
crizotinib
lung

Access to Document

10.1002/cnr2.1483

Cite this

@article{4afc2716de50446f9ec4967243aba348,

title = "Long-term response to crizotinib in a 17-year-old boy with treatment-na{\"i}ve ALK-positive non-small-cell lung cancer",

abstract = "Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80{\textendash}90\% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3{\textendash}7\% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-na{\"i}ve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-na{\"i}ve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.",

keywords = "adenocarcinoma, adolescence, ALK, crizotinib, lung, adenocarcinoma, adolescence, ALK, crizotinib, lung",

author = "G. Megaro and E. Miele and Spinelli, \{G. P.\} and I. Alessi and Del, \{Baldo G.\} and R. Cozza and I. Russo and De, \{Pasquale M. D.\} and Cefalo, \{M. G.\} and P. Toma and A. Carai and Di, \{Ruscio V.\} and De, \{Ioris M. A.\} and Angela Mastronuzzi",

year = "2022",

doi = "10.1002/cnr2.1483",

language = "English",

volume = "5",

pages = "1--4",

journal = "Cancer Reports",

issn = "2573-8348",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer

AU - Megaro, G.

AU - Miele, E.

AU - Spinelli, G. P.

AU - Alessi, I.

AU - Del, Baldo G.

AU - Cozza, R.

AU - Russo, I.

AU - De, Pasquale M. D.

AU - Cefalo, M. G.

AU - Toma, P.

AU - Carai, A.

AU - Di, Ruscio V.

AU - De, Ioris M. A.

AU - Mastronuzzi, Angela

PY - 2022

Y1 - 2022

N2 - Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

AB - Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

KW - adenocarcinoma

KW - adolescence

KW - ALK

KW - crizotinib

KW - lung

KW - adenocarcinoma

KW - adolescence

KW - ALK

KW - crizotinib

KW - lung

UR - https://publicatt.unicatt.it/handle/10807/330096

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85123850853&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123850853&origin=inward

U2 - 10.1002/cnr2.1483

DO - 10.1002/cnr2.1483

M3 - Article

SN - 2573-8348

VL - 5

SP - 1

EP - 4

JO - Cancer Reports

JF - Cancer Reports

IS - 3

ER -

Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this